GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Capex-to-Revenue

U2Bio Co (XKRX:221800) Capex-to-Revenue : 0.07 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is U2Bio Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

U2Bio Co's Capital Expenditure for the six months ended in Dec. 2023 was ₩-937.16 Mil. Its Revenue for the six months ended in Dec. 2023 was ₩13,904.22 Mil.

Hence, U2Bio Co's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.07.


U2Bio Co Capex-to-Revenue Historical Data

The historical data trend for U2Bio Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U2Bio Co Capex-to-Revenue Chart

U2Bio Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.04 0.01 0.01 0.02 0.03

U2Bio Co Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue 0.01 0.03 - 0.07

Competitive Comparison of U2Bio Co's Capex-to-Revenue

For the Diagnostics & Research subindustry, U2Bio Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


U2Bio Co's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, U2Bio Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where U2Bio Co's Capex-to-Revenue falls into.



U2Bio Co Capex-to-Revenue Calculation

U2Bio Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-977.891) / 30792.037
=0.03

U2Bio Co's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-937.157) / 13904.222
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


U2Bio Co  (XKRX:221800) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


U2Bio Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of U2Bio Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


U2Bio Co (XKRX:221800) Business Description

Traded in Other Exchanges
N/A
Address
Basement 1, 68 Gumaro Songpagu, Seoul, KOR
U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.

U2Bio Co (XKRX:221800) Headlines

No Headlines